{"id":"W2513734563","doi":"10.1016/j.cllc.2016.07.007","title":"Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non–Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations","year":2016,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Astellas Foundation for Research on Metabolic Disorders","keywords":"Erlotinib; Medicine; Epidermal growth factor receptor; Lung cancer; Internal medicine; Erlotinib Hydrochloride; Oncology; Placebo; Adverse effect; Pharmacology; Clinical endpoint; Cancer; Randomized controlled trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001998596,0.0002711832,0.0006396679,0.0001769462,0.00007443549,0.0000155921,0.00007868922,0.0001196542,0.0001905864],"category_scores_gemma":[0.00016522,0.0001567179,0.00004663676,0.0004101931,0.0001328229,0.000226323,0.0000279004,0.0002606211,8.201686e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004388237,"about_ca_system_score_gemma":0.00066241,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008990447,"about_ca_topic_score_gemma":0.001866105,"domain_scores_codex":[0.9979304,0.0001284264,0.0007849442,0.0005533583,0.0002920621,0.0003107821],"domain_scores_gemma":[0.9979573,0.0008354086,0.0004659879,0.0002139718,0.0003575642,0.0001697574],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.006812599,0.006754655,0.9596654,0.0001880828,0.0003805382,0.00001343167,0.004112491,0.00002066778,0.0001480559,0.000003994956,0.0001054569,0.02179462],"study_design_scores_gemma":[0.1331778,0.004997971,0.8571212,0.001696739,0.0004271973,8.816765e-7,0.0009629839,0.0004530038,0.0008512052,0.000003358776,0.00003880825,0.0002688674],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944659,0.0001264416,0.0001396088,0.0009092889,0.0001456675,0.003898659,0.0001573397,0.00002683035,0.0001302155],"genre_scores_gemma":[0.9975555,0.0001921615,0.0005277147,0.0002531273,0.00009251734,0.0008745905,0.00004174056,0.000055799,0.0004068799],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1263652,"threshold_uncertainty_score":0.6390771,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02682449255165086,"score_gpt":0.3907059977854347,"score_spread":0.3638815052337838,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}